Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Lancet Infect Dis. 2024 May 28:S1473-3099(24)00289-5. doi: 10.1016/S1473-3099(24)00289-5. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38821073
Pomegranate Peel Extract Attenuates Isoprenaline-Induced Takotsubo-like Myocardial Injury in Rats.
Marinković ST, Đukanović Đ, Duran M, Bajic Z, Sobot T, Uletilović S, Mandić-Kovacević N, Cvjetković T, Maksimović ŽM, Maličević U, Vesić N, Jovičić S, Katana M, Šavikin K, Djuric DM, Stojiljković MP, Škrbić R. Marinković ST, et al. Among authors: katana m. Pharmaceutics. 2023 Jun 9;15(6):1697. doi: 10.3390/pharmaceutics15061697. Pharmaceutics. 2023. PMID: 37376144 Free PMC article.
Cardioprotective effects of liraglutide pretreatment on isoprenaline-induced myocardial injury in rats.
Bajic Z, Sobot T, Uletilovic S, Mandic-Kovacevic N, Cvjetkovic T, Malicevic U, Djukanovic D, Duran M, Vesic N, Avram S, Jovicic S, Katana M, Matavulj A, Ponorac N, Djuric DM, Stojiljkovic MP, Skrbić R. Bajic Z, et al. Among authors: katana m. Can J Physiol Pharmacol. 2023 May 1;101(5):258-267. doi: 10.1139/cjpp-2022-0534. Epub 2023 Feb 27. Can J Physiol Pharmacol. 2023. PMID: 36848640
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20. Lancet HIV. 2022. PMID: 35460601 Free article. Clinical Trial.
15 results